Article Summary
A recent study by the Ethics and Public Policy Center (EPPC) revealed that the abortion pill, mifepristone, causes severe and fatal side effects in women. The study found that 10.9% of women suffered from complications such as sepsis, infection, and hemorrhaging within 45 days of taking the pill. The EPPC emphasized that the mail-order approach to distributing the pill puts women at risk. The study has been met with criticism and efforts to discredit its findings by organizations invested in promoting the use of the abortion pill.
What This Means for You
- Be aware of the potential risks and side effects associated with the abortion pill, including life-threatening complications.
- Be cautious of organizations promoting the use of the abortion pill without mentioning the potential dangers and risks.
- Advocate for policies and regulations that prioritize the safety and well-being of women seeking abortions.
- Stay informed on the latest research and studies related to the abortion pill and its effects on women’s health.
Original Post
Many of us were relieved to learn that Roe v. Wade would no longer be in effect to justify killing babies, but the crusade was on to keep abortions alive by encouraging the use of the abortion pill—and the results have been deadly and disastrous.
The Ethics and Public Policy Center (EPPC) conducted a sophisticated study on mifepristone (the abortion pill) to determine the aftereffects of the drug:
The most comprehensive U.S. study of the abortion pill excluded tens of thousands of insurance claims from its analysis of mifepristone-linked complications to ensure it did not exaggerate the harms the abortion drug could inflict on women.
The exclusion of those data points further legitimizes findings that 10.9 percent of women suffered sepsis, infection, hemorrhaging, or other serious complications within 45 days of a chemical abortion. It also puts to bed criticisms raised by bad-faith actors who questioned researchers’ conclusions that the U.S. Food and Drug Administration should reinstate mifepristone safeguards or potentially rescind its approval altogether.
The researchers, Ryan T. Anderson and Jamie Bryan Hall, made a major effort to exclude incidents that could not be directly ascribed to the abortion pill:
Even with tens of thousands of data exclusions and an ER visit benchmark that nearly matched the abortion drug’s label, Anderson and Hall found the rate of life-threatening complications due to mifepristone is at least 22 times higher than what the FDA and the abortion pill’s manufacturer suggest.
The EPPC emphasized that the mail-order approach to distributing the pill was putting women at risk:
Hall, the center’s director of data analysis, added that about half of the women who experience what’s called an ‘adverse event’ will likely end up in the ER or hospitalized overnight. ‘It’s very risky for her in these situations to be doing this without proper care from a physician throughout the process.’
The EPPC also took additional steps to ensure the legitimacy of their results:
We consider only serious adverse events that occurred within 45 days following the abortion. This is conservative, as some adverse events may present later (and studies relied on by the FDA used a timeframe as long as 72 days).
The EPPC has been explicit about its recommendations to protect
ORIGINAL SOURCE:
Source link
